Loading...
•
Jun 30, 2023
Semler Scientific Q2 2023 Earnings Report
Semler Scientific reported record quarterly revenues and pre-tax net income, driven by sales of QuantaFlo® for peripheral arterial disease testing. The company is focused on developing its business in heart dysfunction.
Key Takeaways
Semler Scientific reported a 25% increase in revenue to $18.6 million and a 44% increase in net income to $5.9 million for Q2 2023 compared to the corresponding period in 2022. The company achieved record quarterly revenues and pre-tax net income, primarily from sales of QuantaFlo®.
Revenue was $18.6 million, an increase of 25% compared to the corresponding period of 2022
Net income was $5.9 million, an increase of 44% compared to the corresponding period of 2022
Cash, cash equivalents and short-term investments of $51.8 million
Highest quarterly revenues and pre-tax net income since inception
Forward Guidance
This press release contains forward-looking statements regarding the development of business in heart dysfunction and diabetes, continued testing of asymptomatic patients, and the benefits of early identification of at-risk patients.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...